Ferroptosis-Inducer Priming of MSCs for Oxidative Stress Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poor survival rate of transplanted mesenchymal stem cells (MSCs) due to oxidative stress in donor or acceptor microenvironments and the challenge of maintaining regenerative potential during in vitro expansion for large-scale manufacturing in cell-based therapeutics.
Innovation Solution
A method involving the use of ferroptosis inducers like erastin and sulfasalazine to precondition human MSCs, enhancing their proliferation and oxidative stress tolerance by culturing them in xeno-free medium and treating with low-dose priming agents to maintain CD73, CD90, and CD105 positivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If MSCs are expanded in vitro for large-scale manufacturing, then the quantity of MSCs increases, but the regenerative potential and stemness are compromised
Solution Approach 1:
The patent applies preliminary action by pre-treating MSCs with ferroptosis inducers (erastin or sulfasalazine) before transplantation. This pre-conditioning primes the cells to resist oxidative stress in the target microenvironment, thereby maintaining their regenerative potential while enabling large-scale expansion. The pre-treatment creates a protective effect that persists through the expansion process, allowing both high productivity and preserved stemness.
2Adaptability or versatility
If MSCs are transplanted into oxidative stress microenvironment, then the therapeutic application is achieved, but the survival rate of transplanted cells decreases
Solution Approach 1:
The patent implements preliminary anti-action by exposing MSCs to low-dose ferroptosis inducers that trigger adaptive responses against oxidative stress. This pre-conditioning creates protective mechanisms within the cells before they encounter the harsh oxidative microenvironment at the transplantation site. The cells are pre-armed with antioxidant defenses and stress resistance mechanisms, thereby significantly improving their survival rate while maintaining their therapeutic functionality.
3Object-affected harmful factors
If ferroptosis inducers are used to precondition MSCs, then the oxidative stress tolerance increases, but the cell viability may be affected at high concentrations
Solution Approach 1:
The patent applies parameter changes by precisely controlling the concentration and exposure time of ferroptosis inducers. Low doses of erastin (0.1-10 μM) or sulfasalazine (0.01-1 mM) are used for brief periods (6-48 hours) to trigger protective adaptive responses without causing lethal ferroptosis. This dosing strategy transforms the parameter range from cytotoxic to cytoprotective, enabling the cells to develop oxidative stress tolerance while maintaining high viability. The patent identifies specific concentration thresholds that differentiate between protective preconditioning and harmful cell death.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a 1.4-fold increase in MSC proliferation rate and improved oxidative stress tolerance, preserving stemness markers and enhancing therapeutic potential for transplantation into inflammatory or oxidative microenvironments.
Implementation Method 1
ferroptosis inducers (FINs) precondition treatment
Implementation Method 2
poor survival rate of transplanted cells, primarily due to the donor or acceptor, ROS-rich microenvironment at injury sites
Data Source
AI summary
A method for producing an enriched population of human MSCs, comprising culturing isolated MSCs in xeno-free medium to at least 80% confluence, followed by treatment with a priming agent: erastin, sulfasalazine, or a combination thereof, to produce expanded MSCs positive for CD73, CD90, and CD105. A method is also provided for treating or preventing tissue damage or dysfunction, comprising the aforementioned method involving priming of human MSCs with a low dose of a priming agent. Further, a composition comprising primed MSCs and a cell culture medium system including the priming agent. Accordingly, the low-dose FINs offer a novel approach as a priming agent in large-scale stem cell expansion process. And the primed MSCs after low-dose FINs treatment could be applied to transplantation into oxidative and inflammatory microenvironments.